Curzion Pharmaceuticals Acquired by Horizon Therapeutics

BURLINGTON, Mass., May 6, 2015 – CoLucid Pharmaceuticals, Inc. (“CoLucid”) (CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, lasmiditan, for the acute treatment of migraine headaches, announced today the pricing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $10.00 per share.